BD

BD (NYSE:BDX) touted a study on innovation in flow cytometry that featured as the cover story of the journal Science. Franklin Lakes, New Jersey-based BD’s study was conducted in collaboration with the European Molecular Biology Laboratory (EMBL). It evaluated BD’s flow cytometry efforts that add fluorescence imaging and image-based decision-making to sort individual cells at high…

BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps in diagnostic testing in AMR…

A life sciences real estate developer announced today that BD (NYSE:BDX) selected its property as a new facility for its biosciences business. Through a joint venture with Tishman Speyer and Bellco Capital, Breakthrough Properties confirmed that BD chose its Torrey View by Breakthrough property for an expanded San Diego reagent innovation center within its biosciences segment. Get…

Flow cytometry is a powerful technology given its ability to analyze the physical and chemical properties of cells and particles. But many laboratories struggle to find space for advanced flow cytometry cell analyzers. BD (NYSE:BDX) has responded to that challenge with its benchtop FACSymphony A1 cell analyzer. BD designed the fluorescence-activated cell analyzer to support…

Becton Dickinson (NYSE:BDX) announced today that it’s received an FDA emergency use authorization for its COVID-19 antigen test, which the company will start shipping this week. BD plans to ramp-up manufacturing capacity to 2 million tests per week by the end of September, with 10 million tests produced by the end of September. The tests run…